Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Corporations (2)
- Hatch-Waxman Act (2)
- Incentives (2)
- Patent law (2)
- Research and development (2)
-
- Administrative proceedings (1)
- Antitrust (1)
- Biotechnology (1)
- Brand names (1)
- Case law (1)
- Competition (1)
- Compromise (1)
- Congress (1)
- Exclusivity (1)
- Exclusivity parking (1)
- Federal agencies (1)
- Forfeiture (1)
- Generic drugs (1)
- Generics (1)
- Law reform (1)
- Legislative intent (1)
- Medicare Prescription Drug Improvement and Modernization Act (1)
- Medicine (1)
- Microbes (1)
- Microbiomes (1)
- Patent challenges (1)
- Patent protection (1)
- Patentability (1)
Articles 1 - 3 of 3
Full-Text Articles in Intellectual Property Law
The Uneasy Case For Patent Law, Rachel E. Sachs
The Uneasy Case For Patent Law, Rachel E. Sachs
Michigan Law Review
A central tenet of patent law scholarship holds that if any scientific field truly needs patents to stimulate progress, it is pharmaceuticals. Patents are thought to be critical in encouraging pharmaceutical companies to develop and commercialize new therapies, due to the high costs of researching diseases, developing treatments, and bringing drugs through the complex, expensive approval process. Scholars and policymakers often point to patent law’s apparent success in the pharmaceutical industry to justify broader calls for more expansive patent rights.
This Article challenges this conventional wisdom about the centrality of patents to drug development by presenting a case study of …
An Administrative Meter Maid: Using Inter Partes Review And Post-Grant Review To Curb Exclusivity Parking Via The "Failure To Market" Provision Of The Hatch-Waxman Act, Brian T. Apel
Michigan Law Review
Congress created the unique Hatch-Waxman framework in 1984 to increase the availability of low-cost generic drugs while preserving patent incentives for new drug development. The Hatch-Waxman Act rewards generic drug companies that successfully challenge a pharmaceutical patent: 180 days of market exclusivity before any other generic firm can enter the market. When a generic firm obtains this reward, sometimes drug developers agree to pay generic firms to delay entering the market. These pay-for-delay agreements give rise to exclusivity parking and run counter to congressional intent by delaying full generic drug competition. The Medicare Prescription Drug, Improvement, and Modernization Act created …
Unsettling Drug Patent Settlements: A Framework For Presumptive Illegality, Michael A. Carrier
Unsettling Drug Patent Settlements: A Framework For Presumptive Illegality, Michael A. Carrier
Michigan Law Review
A tidal wave of high drug prices has recently crashed across the U.S. economy. One of the primary culprits has been the increase in agreements by which brand-name drug manufacturers and generic firms have settled patent litigation. The framework for such agreements has been the Hatch-Waxman Act, which Congress enacted in 1984. One of the Act's goals was to provide incentives for generics to challenge brand-name patents. But brand firms have recently paid generics millions of dollars to drop their lawsuits and refrain from entering the market. These reverse-payment settlements threaten significant harm. Courts nonetheless have recently blessed them, explaining …